SGEN


Merck To Buy $1B Seattle Genetics Stake For Oncology Collab

Seattle Genetics (SGEN) shares are up 9% in pre-market hours today following the news that Merck will make a $1 billion equity investment …

With FDA Approvals in Hand, These 2 Biotech Stocks Are on Wall Street’s Radar

And we have a winner. After a long and arduous development process, only a few biotech names will emerge having attained the ultimate …

Seattle Genetics’ Breast Cancer Drug Approved Months Ahead of Schedule

Seattle Genetics (SGEN) has announced that its drug TUKYSA (tucatinib) has been approved by the FDA for metastatic HER2 positive breast cancer patients, …

Goldman Sachs: 3 Stocks to Buy Despite Recession Fears

A recession could be headed your way, warns Goldman Sachs — and that’s okay. In a recent report, Goldman private wealth management chief …

J.P. Morgan Gives Thoughts on Seattle Genetics, Inc. (SGEN) Following Phase 3 Results

Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) are tumbling nearly 10% in Monday’s trading session, after the drug maker announced topline data from its ECHELON-1 Phase …

J.P. Morgan Comments on Immunomedics, Inc. (IMMU) and Seattle Genetics (SGEN) Deal

This morning, Immunomedics, Inc. (NASDAQ:IMMU) and Seattle Genetics, Inc.

Cantor Signals Caution on Seattle Genetics, Inc (SGEN) Following Partial FDA Hold on AML Drug

Cantor analyst Mara Goldstein sheds light on Seattle Genetics, Inc. (NASDAQ:SGEN) after the bad news broke of a FDA partial hold placed on clinical …

Company Update (NASDAQ:SGEN): Seattle Genetics, Inc. Reports Fourth Quarter and Year 2015 Financial Results

Seattle Genetics, Inc. (NASDAQ:SGEN) reported financial results for the fourth quarter and year ended December 31, 2015.

Seattle Genetics, Inc. (SGEN) Reports 2Q15 Financial Results

Seattle Genetics, Inc. (NASDAQ:SGEN) reported financial results for the second quarter and six months ended June 30, 2015.

Company Update (NASDAQ:SGEN): Seattle Genetics, Inc. Initiates Clinical Trial of ADCETRIS® in Systemic Lupus Erythematosus, a Chronic Autoimmune Disease

Seattle Genetics, Inc. (NASDAQ:SGEN) announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus).

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts